Clearmind Medicine Secures European Patent Publication for Psychedelic-Based Cocaine Addiction Therapy
Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0), a clinical-stage biotechnology firm focused on the development of next-generation psychedelic-based treatments, has officially announced the publication of a European patent application for its novel cocaine addiction therapy. The patent, filed with the European Patent Office (EPO) under number EP 4531826, represents a critical milestone in the company’s […]